Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis
- PDF / 617,836 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 26 Downloads / 192 Views
Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis Menha Swellam 1,2
&
Noha M. Bakr 1,2 & Hekmat M. El Magdoub 3
&
Marwa S. Hamza 4,5
&
Lobna R. Ezz El Arab 6
Received: 21 July 2020 / Accepted: 7 September 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Serum miRNAs (miRs) have gained consideration as encouraging molecular markers for cancer diagnosis and prediction of prognosis. The authors aimed to identify the exact role of miR-17-5p, miR-125b, and miR-221 among glioblastoma multiforme (GBM) patients before and after standard treatment, and correlate their expression with survival pattern. The study included 25 GBM patients and 20 healthy controls. Serum miR-17-5p, miR-125b, and miR-221 expression were analyzed before and after treatment using quantitative real-time polymerase chain reaction (qPCR). The diagnostic efficacy for the tested miRs was evaluated using the receiver operating characteristic (ROC) curve, and the relation of miRs expression versus clinical criteria for GBM was assessed. Patients’ survival patterns were examined versus miRs expression levels. A significant difference was reported between miRs expression among the enrolled individuals. Both miR-17-5p and miR-221 reported significant elevations in GBM patients who: are above 60 years old, underwent biopsy resection, have a non-frontal lesion, with tumor size above 5 cm, and with performance status equals 2 according to the Eastern Cooperative Oncology Group (ECOG) Performance Status. With regard to miR-125b, a significant difference was detected according to surgery strategy, primary lesion of the tumor, and ECOG status. MiRs levels were significantly decreased for GBM patients after treatment. Survival patterns demonstrated an increase in miR-17-5p, miR-125b, and miR-221 in GBM patients with worse progression-free survival and among those with worse overall survival. Detection of serum miR-17-5p, miR-125b, and miR-221 aids in the prediction of prognosis and response to treatment strategy for GBM patients. Keywords Liquid biopsy . miR-17-5p . miR-125b . miR-221 . GBM . Prediction . Response
Introduction * Hekmat M. El Magdoub [email protected]; [email protected] 1
Biochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Giza, Dokki, Egypt
2
High Throughput Molecular and Genetic Laboratory, Centers of Excellence for Advanced Sciences, National Research Centre, Giza, Dokki, Egypt
3
Biochemistry Department, Faculty of Pharmacy, Translational Research Unit, Misr International University, Cairo, Egypt
4
Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt
5
The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt
6
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Glioblastoma multiforme
Data Loading...
